Daiichi Sankyo: sac-TMT has reported positive topline of OptiTROP-Lung06 PFS, yet too early to conclude Trop2 ADC showdown in 1L NSCLC

Research evidence excerpt

Daiichi Sankyo: sac-TMT has reported positive topline of OptiTROP-Lung06 PFS, yet too early to conclude Trop2 ADC showdown in 1L NSCLC

jurisdictions or to certain categories of investors where that

permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may

be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or

located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary

to law or regulation or would subject the entities noted herein to any regulation or licensing requirement within such jurisdiction.

Source: Bloomberg Index Services Limited. BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its

affiliates (collectively “Bloomberg”). Bloomberg or Bloomberg’s licensors own all proprietary rights in the Bloomberg Indices.

Neither Bloomberg nor Bloomberg’s licensors approves or endorses this material, or guarantees the accuracy or completeness of

any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum

extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.

No part of this material may be reproduced, distributed or transmitted or otherwise made available without prior consent of the

entities noted herein. Copyright Bernstein Institutional Services LLC Bernstein Autonomous LLP, BSG France S.A., Sanford C.

Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private

Limited (SEBI registration no.